X4 Pharmaceuticals (XFOR): CEO sold ~$13K

~$13K

Approx. value · 32K sh @ $0.3945

994K

Holds after · shares reported

Traded

Nov 15, 2024

Filed

Nov 19, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 7, 2024Insider · 5 peopleInsiders: 5 sales (~$347K)
2. Oct 15, 2024InsiderCEO sold ~$18K of XFOR shares in the open market
3. Nov 15, 2024 · this disclosureInsiderCEO sold ~$13K of XFOR shares in the open market

What came next

1. Jan 24, 2025Insider · 5 peopleInsiders: 5 sales (~$97K)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for X4 Pharmaceuticals

For X4 Pharmaceuticals, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its XFOR page.

Other recent filings by Paula Ragan, President and CEO

• SEC Form 4 at X4 Pharmaceuticals (XFOR)Jan 27, 2025
• SEC Form 4 at X4 Pharmaceuticals (XFOR)Oct 16, 2024
• SEC Form 4 at X4 Pharmaceuticals (XFOR)Oct 8, 2024

The full history of Paula Ragan, President and CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at X4 Pharmaceuticals

• SEC Form 4Oct 19, 2026
• SEC Schedule 13GOct 7, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 4Aug 14, 2026
• SEC Form 4Aug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its XFOR page.